Art

J-GLOBAL ID：201902257446305915   Reference number：19A2183491

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study

多発性硬化症におけるリツキシマブの安全性と有効性:後ろ向き観察研究【JST・京大機械翻訳】

Author (6)： Yamout Bassem I. (Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon) ,  El-Ayoubi Nabil K. (Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon) ,  Nicolas Johny (Faculty of Medicine, American University of Beirut, Lebanon) ,  El Kouzi Yehya (Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon) ,  Khoury Samia J. (Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon) ,  Zeineddine Maya M. (Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon)
Material： Journal of Immunology Research (Web)  (J Immunol Res (Web))
Volume： 2018  Page： Null  Publication year： 2018 
JST Material Number： U7019A  ISSN： 2314-8861  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Objective. To evaluate the eff...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2183491&from=J-GLOBAL&jstjournalNo=U7019A") }}

Thesaurus term： therapy ,  adult(person) ,  effect ,  *safety ,  NMR imaging ,  *effectiveness ,  remission ,  follow-up study ,  population(statistics) ,  recurrence ,  human(primates) ,  *multiple sclerosis ,  tolerability
Semi thesaurus term： 有害事象 ,  再発率 ,  *リツキシマブ , 【Automatic Indexing@JST】

JST classification (1)： Immunologic diseases,allergic diseases in general.  (GD04010C)

Reference (23)：

• A. Shwarz, B. Balint, M. Korporal-Kuhnke, S. Jarius, K. Von Engelhardt, A. Furwentshes, "B cell populations discriminate between pediatric-and-adult-onset multiple sclerosis," Neurology Neuroimmunology & Neuroinflammation, vol. 4, no. 1, article e309, 2016.
• H. F. Petreit, W. Moeller Hartmann, D. Reske, A. Rubbert, "Rituximab in a patient with multiple sclerosis-effect on B cells, plasma cells and intrathecal IgG synthesis," Acta Neurologica Scandinavica, vol. 117, no. 6, pp. 399-403, 2008.
• S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C. H. Smith, HERMES Trial Group., "B-cell depletion with rituximab in relapsing-remitting multiple sclerosis," The New England Journal of Medicine, vol. 358, no. 7, pp. 676-688, 2008.
• K. Hawker, P. O'Connor, M. S. Freedman, P. A. Calabresi, J. Antel, J. Simon, S. Hauser, E. Waubant, T. Vollmer, H. Panitch, J. Zhang, P. Chin, C. H. Smith, OLYMPUS trial group, "Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial," Annals of Neurology, vol. 66, no. 4, pp. 460-471, 2009.
• S. L. Hauser, A. Bar-Or, G. Comi, G. Giovannoni, H. P. Hartung, B. Hemmer, F. Lublin, X. Montalban, K. W. Rammohan, K. Selmaj, A. Traboulsee, J. S. Wolinsky, D. L. Arnold, G. Klingelschmitt, D. Masterman, P. Fontoura, S. Belachew, P. Chin, N. Mairon, H. Garren, L. Kappos, OPERA I and OPERA II Clinical Investigators., "Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis," The New England Journal of Medicine, vol. 376, no. 3, pp. 221-234, 2017.

Terms in the title (6)： 多発性硬化症 ,  リツキシマブ ,  安全性 ,  有効性 ,  観察 ,  研究